Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Anders notes that in the primary KEYNOTE-905 analysis the control arm had grade 3 or higher adverse events in the 40-50% range, likely from surgery alone. That makes the 44% neoadjuvant rate with EV plus pembrolizumab look less alarming than a simple cross-arm comparison might suggest.

Related Insights

Contrary to concerns about tolerating Enfortumab Vedotin (EV) after major surgery, 80% of muscle-invasive bladder cancer patients who began the adjuvant phase in the KEYNOTE B15 trial successfully completed it. This suggests the regimen is more manageable post-cystectomy than anticipated.

Surgeons may find cystectomies challenging after neoadjuvant EV-Pembro. This difficulty is not a drug side effect but a consequence of high efficacy. The therapy makes previously unresectable tumors operable, forcing surgeons to operate on fibrotic, remnant tissue, which is an inherently more difficult procedure.

The 6% two-year landmark OS benefit for EV Pembro in the B15 trial appears modest compared to other EV Pembro studies. However, this is due to comparing it against an active, effective control (GEM-CIS chemotherapy), unlike trials that used surgery alone, reinforcing the value of neoadjuvant therapy overall.

The practice-changing Keynote B15 trial showed strong efficacy for neoadjuvant EV-Pembro. However, about half of patients discontinued treatment due to side effects. This creates a clinical paradox: patients who complete the full regimen may be over-treated, while those who stop early due to toxicity may be under-treated, complicating patient management and counseling.

Despite the perception that cisplatin-ineligible patients have worse disease biology, the pathologic complete response rates to neoadjuvant EV Pembro were nearly identical (56-57%) in both cis-ineligible (KEYNOTE-905) and cis-eligible (KEYNOTE-B15) trials. This suggests the regimen's high efficacy may overcome underlying biological differences.

Neoadjuvant EV-Pembro yields pathologic complete response rates near 60% in muscle-invasive bladder cancer. This high efficacy has prompted multiple large-scale clinical trials to test whether radical cystectomy can be safely avoided in select patients, a potentially practice-defining change.

While KEYNOTE-905 showed dramatic survival benefits with neoadjuvant plus adjuvant EV-pembrolizumab, its design makes it impossible to isolate the benefit of each phase. The high (57%) pathologic complete response after neoadjuvant therapy alone suggests many patients may be overtreated with adjuvant cycles, risking unnecessary long-term toxicity like neuropathy.

In cisplatin-ineligible muscle-invasive bladder cancer, neoadjuvant enfortumab vedotin plus pembrolizumab demonstrated a 57% pathologic complete response rate in the KEYNOTE-905 trial. This is an unprecedented result, significantly higher than any previously studied regimen and signals a major shift in perioperative treatment.

Tom reads the hazard ratios as a near-exact stepwise drop: 0.71 for pembrolizumab versus cystectomy and 0.40 for EV plus pembrolizumab, with each component apparently contributing about 0.3. He cautions the 85-patient arms are small, but says the EFS curves visually support this additive pattern.

With pathologic complete response rates approaching 67% in patients completing neoadjuvant EV-Pembro, a majority of cystectomies are now removing cancer-free bladders. This creates an ethical and clinical imperative to rapidly launch prospective trials to validate bladder preservation strategies and avoid overtreatment.